Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myeloma

Abstract Multiple myeloma (MM) is a blood cancer characterized by the clonal evolution of plasma cells. In 2022, there were an estimated 118 000 MM cases and 121 000 deaths worldwide. The treatment landscape of MM has undergone a dramatic transformation in recent decades, shifting from conventional...

Descrición completa

Detalles Bibliográficos

Principais autores:	David Kegyes, Anamaria Bancos, Adrian Bogdan Tigu, Ioana Rus, Delia Dima, Diana Cenariu, Madalina Nistor, Raluca Munteanu, Diana Gulei, Alina Tanase, Anca Colita, Anca Buzoianu, Cristina Iuga, Mihnea Zdrenghea, Evangelos Terpos, Stefan O. Ciurea, Aaron Ciechanover, Hermann Einsele, Ciprian Tomuleasa
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2025-08-01
Series:	Biomarker Research
Assuntos:	Multiple myeloma CELMoD Iberdomide CC-220 Mezigdomide CC-92480
Acceso en liña:	https://doi.org/10.1186/s40364-025-00825-8
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!